Rep. Jefferson Shreve Purchases Edwards Lifesciences Co. (NYSE:EW) Shares

Representative Jefferson Shreve (R-Indiana) recently bought shares of Edwards Lifesciences Co. NYSE: EW. In a filing disclosed on May 08th, the Representative disclosed that they had bought between $15,001 and $50,000 in Edwards Lifesciences stock on April 7th. The trade occurred in the Representative's "CRT - STANDARD UNIT TRUST" account.

Representative Jefferson Shreve also recently made the following trade(s):

• Purchased $50,001 - $100,000 in shares of Chipotle Mexican Grill NYSE: CMG on 4/17/2025.
• Purchased $50,001 - $100,000 in shares of Applied Materials NASDAQ: AMAT on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Caterpillar NYSE: CAT on 4/17/2025.
• Sold $15,001 - $50,000 in shares of Lululemon Athletica NASDAQ: LULU on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Western Digital NASDAQ: WDC on 4/17/2025.
• Sold $15,001 - $50,000 in shares of Zoetis NYSE: ZTS on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Stryker NYSE: SYK on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 4/17/2025.
• Purchased $15,001 - $50,000 in shares of Ross Stores NASDAQ: ROST on 4/17/2025.

Edwards Lifesciences Stock Performance

EW stock traded down $0.81 on Friday, reaching $73.82. The company's stock had a trading volume of 3,814,732 shares, compared to its average volume of 5,031,137. The firm has a fifty day moving average of $71.48 and a two-hundred day moving average of $71.50. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. The company has a market capitalization of $43.40 billion, a P/E ratio of 10.59, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. The company had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company's quarterly revenue was up 6.2% compared to the same quarter last year. During the same period last year, the company earned $0.66 earnings per share. As a group, analysts predict that Edwards Lifesciences Co. will post 2.45 EPS for the current fiscal year.

Institutional Trading of Edwards Lifesciences

Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Edwards Lifesciences by 10.4% in the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company's stock worth $5,117,845,000 after buying an additional 6,537,494 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Edwards Lifesciences by 5.3% during the fourth quarter. Wellington Management Group LLP now owns 33,210,879 shares of the medical research company's stock worth $2,458,601,000 after acquiring an additional 1,678,154 shares in the last quarter. Geode Capital Management LLC boosted its position in Edwards Lifesciences by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 13,647,341 shares of the medical research company's stock valued at $1,007,520,000 after purchasing an additional 126,194 shares during the last quarter. Jennison Associates LLC grew its stake in Edwards Lifesciences by 34.3% in the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock valued at $731,036,000 after purchasing an additional 2,576,383 shares in the last quarter. Finally, Fisher Asset Management LLC increased its position in Edwards Lifesciences by 7.7% in the 4th quarter. Fisher Asset Management LLC now owns 9,775,276 shares of the medical research company's stock worth $723,664,000 after purchasing an additional 696,965 shares during the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Bernard J. Zovighian sold 6,164 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The shares were sold at an average price of $69.51, for a total value of $428,459.64. Following the completion of the sale, the chief executive officer now owns 59,083 shares of the company's stock, valued at approximately $4,106,859.33. The trade was a 9.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Daniel J. Lippis sold 400 shares of the firm's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $69.48, for a total value of $27,792.00. Following the transaction, the vice president now owns 22,588 shares in the company, valued at approximately $1,569,414.24. This trade represents a 1.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 89,681 shares of company stock worth $6,492,703 in the last three months. 1.29% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Robert W. Baird raised their price objective on shares of Edwards Lifesciences from $72.00 to $75.00 and gave the company a "neutral" rating in a research note on Thursday, April 24th. Truist Financial dropped their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Wolfe Research lowered Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a report on Wednesday, February 12th. Piper Sandler raised shares of Edwards Lifesciences from a "neutral" rating to an "overweight" rating and upped their price target for the company from $73.00 to $80.00 in a report on Thursday, April 24th. Finally, StockNews.com raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a research note on Thursday. One analyst has rated the stock with a sell rating, twelve have given a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $79.45.

About Representative Shreve

Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election. Email editor@ballotpedia.org to notify us of updates to this biography. Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive. Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.